-$0.11 Earnings Per Share Expected for Cerus Co. (NASDAQ:CERS) This Quarter

Equities research analysts expect Cerus Co. (NASDAQ:CERS) to report earnings of ($0.11) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Cerus’ earnings, with estimates ranging from ($0.12) to ($0.10). Cerus also posted earnings of ($0.11) per share during the same quarter last year. The firm is expected to report its next earnings report on Thursday, November 7th.

On average, analysts expect that Cerus will report full year earnings of ($0.48) per share for the current year, with EPS estimates ranging from ($0.50) to ($0.43). For the next year, analysts expect that the company will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.46) to ($0.25). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Cerus.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. Cerus had a negative net margin of 98.69% and a negative return on equity of 85.73%. The firm’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.10) earnings per share.

CERS has been the topic of a number of recent research reports. Stifel Nicolaus started coverage on Cerus in a report on Tuesday, August 27th. They set a “buy” rating and a $7.00 price objective on the stock. ValuEngine raised Cerus from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Zacks Investment Research raised Cerus from a “sell” rating to a “hold” rating in a report on Monday, October 7th. BidaskClub downgraded Cerus from a “hold” rating to a “sell” rating in a report on Friday, October 4th. Finally, Stephens started coverage on Cerus in a report on Thursday, August 22nd. They issued an “overweight” rating and a $8.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $7.63.

In other Cerus news, Director Timothy B. Anderson sold 18,795 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $5.40, for a total transaction of $101,493.00. Following the completion of the sale, the director now owns 177,649 shares in the company, valued at approximately $959,304.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Richard J. Benjamin sold 16,444 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $5.01, for a total transaction of $82,384.44. The disclosure for this sale can be found here. Insiders have sold a total of 74,903 shares of company stock valued at $394,513 in the last quarter. Corporate insiders own 7.26% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Trust N.A. increased its position in shares of Cerus by 57.1% in the 2nd quarter. Raymond James Trust N.A. now owns 22,000 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 8,000 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Cerus by 4.6% in the 2nd quarter. Primecap Management Co. CA now owns 11,300,000 shares of the biotechnology company’s stock valued at $63,506,000 after buying an additional 500,000 shares in the last quarter. Peregrine Capital Management LLC increased its position in shares of Cerus by 13.4% in the 2nd quarter. Peregrine Capital Management LLC now owns 2,194,628 shares of the biotechnology company’s stock valued at $12,334,000 after buying an additional 259,932 shares in the last quarter. Fosun International Ltd increased its position in shares of Cerus by 34.2% in the 2nd quarter. Fosun International Ltd now owns 669,245 shares of the biotechnology company’s stock valued at $3,306,000 after buying an additional 170,707 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Cerus by 0.3% in the 2nd quarter. Vanguard Group Inc. now owns 7,006,902 shares of the biotechnology company’s stock valued at $39,378,000 after buying an additional 23,356 shares in the last quarter. Institutional investors and hedge funds own 72.93% of the company’s stock.

NASDAQ CERS traded up $0.02 during trading on Monday, reaching $4.49. 589,108 shares of the company traded hands, compared to its average volume of 860,230. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.33 and a current ratio of 2.67. The stock’s 50 day moving average price is $4.91 and its two-hundred day moving average price is $5.33. The company has a market cap of $627.23 million, a price-to-earnings ratio of -10.19 and a beta of 1.64. Cerus has a 1-year low of $4.29 and a 1-year high of $6.88.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Article: Quantitative Easing

Get a free copy of the Zacks research report on Cerus (CERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.